ADAMTS5 and arthropathy: These discrepancies are likely the result of the cited authors’ qualification of patients into three types of arthropathy, different disease duration, and inconsistent pharmacotherapy, which might determine the turnover of the ECM, since we have shown that COMP metabolism in patients with JIA, both before and during ETA therapy, remains related to the activity of proteolytic processes, stimulated by ADAMTS4 and ADAMTS5 concentrations, as well as anabolic processes, related to PDGF-BB concentrations.